1993
Cyclosporine treatment of refractory T‐cell lymphomas
Cooper D, Braverman I, Sarris A, Durivage H, Saidman B, Davis C, Hait W. Cyclosporine treatment of refractory T‐cell lymphomas. Cancer 1993, 71: 2335-2341. PMID: 8453556, DOI: 10.1002/1097-0142(19930401)71:7<2335::aid-cncr2820710727>3.0.co;2-d.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaPeripheral T-cell lymphomaRefractory T-cell lymphomaT-cell lymphomaMost patientsDisease progressionReinstitution of therapySubsequent graft rejectionPhase II trialT cell expansionT-cell neoplasmsTranscription of cytokinesCyclosporine treatmentClinical remissionII trialPrevious therapyRecurrent diseaseCsA administrationGraft rejectionRenal toxicityAntiinflammatory effectsRapid recurrenceTransplanted organsInterleukin-2Radiation therapy
1983
Classification and Therapy of Atrophie Blanche
Milstone L, Braverman I, Lucky P, Fleckman P. Classification and Therapy of Atrophie Blanche. JAMA Dermatology 1983, 119: 963-969. PMID: 6651312, DOI: 10.1001/archderm.1983.01650360009005.Peer-Reviewed Original ResearchConceptsAtrophie blancheCommon pathologic eventEndogenous fibrinolytic activityCharacteristic histopathologic featuresPlatelet thrombus formationOcclusion of vesselsMost patientsClinical evolutionHistopathologic featuresPurpuric papulesClinicopathologic entityLower extremitiesPathologic eventsDeep dermisThrombus formationFibrinolytic activityMultiple causesTherapyTreatmentCauseUlcerationPatientsPapulesPathogenesisDisease